Your SlideShare is downloading. ×
Benefits of engaging with the Specialised Services Commissioning Innovation Fund
Benefits of engaging with the Specialised Services Commissioning Innovation Fund
Benefits of engaging with the Specialised Services Commissioning Innovation Fund
Benefits of engaging with the Specialised Services Commissioning Innovation Fund
Benefits of engaging with the Specialised Services Commissioning Innovation Fund
Benefits of engaging with the Specialised Services Commissioning Innovation Fund
Benefits of engaging with the Specialised Services Commissioning Innovation Fund
Benefits of engaging with the Specialised Services Commissioning Innovation Fund
Benefits of engaging with the Specialised Services Commissioning Innovation Fund
Benefits of engaging with the Specialised Services Commissioning Innovation Fund
Benefits of engaging with the Specialised Services Commissioning Innovation Fund
Benefits of engaging with the Specialised Services Commissioning Innovation Fund
Benefits of engaging with the Specialised Services Commissioning Innovation Fund
Benefits of engaging with the Specialised Services Commissioning Innovation Fund
Benefits of engaging with the Specialised Services Commissioning Innovation Fund
Benefits of engaging with the Specialised Services Commissioning Innovation Fund
Benefits of engaging with the Specialised Services Commissioning Innovation Fund
Benefits of engaging with the Specialised Services Commissioning Innovation Fund
Benefits of engaging with the Specialised Services Commissioning Innovation Fund
Benefits of engaging with the Specialised Services Commissioning Innovation Fund
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Benefits of engaging with the Specialised Services Commissioning Innovation Fund

495

Published on

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
495
On Slideshare
0
From Embeds
0
Number of Embeds
5
Actions
Shares
0
Downloads
7
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • Innovation Health and Wealth DH, Dec 2011 included a recommendation to the NHS CB to create an innovation fund for specialised servicesNHS CB Legal Duty to promote research and innovation - including invention , adoption and diffusion of good practice NHS CB ambition to achieve equity and excellence in the provision of specialised care and treatment through excellent commissioning, accelerated by the opportunity to manage new innovations and introduction of technologies in a systematic way that is patient centredThe Mandate: from the Government to the NHS CB to free local organisations and staff to innovate and improveRequirement on the NHS CB to design the commissioning of specialised services in line with direction set out by Sir David Carter’s 2006 independent review
  • Innovations which are in the invention or diffusion stages, including research, are out of scope.Innovations which are in the first four parts of the adoption phase as shown here are in scope.
  • Promise = potential to deliver high impact change if adopted Nationally
  • Value = improved outcomes, cost savings, activity impacts savings.Available for use – i.e. Licenced – off label considered but not unlicensedPrescribed services (> old spec servs – includes services that need to be carried out at specialist centres) commissioned at a national level
  • SCG decisions often not even evidence based, but based on clinical feel an local affordabilityOpportunity to partner with the NHS to generate the evidence needed to inform robust commissioning decisions that will lastProjects could study sub-groups for whom better outcomes are likely - unlike a NICE appraisal which mainly looks at the data for the broader licensed indication
  • In short the SSCIF will determine the true value of an innovation specific to its use in the NHS
  • This meeting is about partnership and the SSCIF epitomises thisWhy is joint investment the answer – State Aid issuesFunding from applicant not necessarily monetary – can be resource, product etc. Joint investment proposal to be made by applicant and will be considered during the review of the application – and if application reached the final stage will be discussed with the Fund decision panel.In additio
  • SSCIF is looking for high impact innovations and any evaluation which supports the promise of the evaluation will be very attractive to NHS England Board and acting an such a commissioning policy will be high priority.Exclusivity terms and discounted purchase price – equate to a volume discount and will be discussed with the SSCIF panel either upfront or post evaluation project (as project may be negative)Risks – negative evaluation project will result in a negative commissioning policy and complete loss of market Intermediate projects may identify sub-groups which will be the focus of a commissioning policyTHE SSCIF Team and the relevant CRG will decide on the scope of any commissioning policy.Partnership will extend to commissioning arrangements post SSCIF evaluation
  • Transcript

    • 1. Benefits of engaging with theSpecialised ServicesCommissioning InnovationFund (SSCIF)Andrew Jones, Senior Medical Science Manager| Bristol-Myers SquibbBernie Stocks, Associate Director, Innovation Adoption, Specialised Services |NHS England
    • 2. Specialised Services InnovationBernie Stocks13 June 2013
    • 3. Specialised Services Innovation ‘job card’3IHW:Create aninnovationfundLegal Duty topromoteresearch andinnovationNHSEnglandAmbition:equity&excellence-specialisedcareTheMandateThe CarterReviewhttp://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_131784.pdfhttp://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4135216.pdfhttp://mandate.dh.gov.uk/NHS | ABPI | 13 04 13
    • 4. 4Specialised ServicesCommissioning InnovationFund (SSCIF)
    • 5. SSCIFFor innovations:Which are new to NHS specialised services or applied in a way that is newto NHS specialised servicesThat have shown promise of delivering an improvement in the quality orcost and affordability of service deliveryWhich have a clearly defined value proposition and, if a service or product,have reached entry levels of safety ready for evaluation in clinical practice.SSCIF Evaluation ProjectsWill be rapid, typically ranging from six to 18 monthsCan involve collaboration between commissioners, clinicians, patients,innovators and the commercial sector5
    • 6. SSCIF – Prime Objective• To generate missing data and information on the impact of the innovation on: Quality, Cost and affordability and NHS activity levels…which can be used to inform commissioning policy• By rapidly evaluation in a clinical, healthcare service setting, innovativemodels of care, pathways, approaches, devices, technologies, products andmedicines with the potential to deliver high impact change for NHSspecialised services6
    • 7. • Idea• Design• PrototypeInvention• Safety Testing• Effectiveness Evaluation• Effectiveness Testing• Innovation Implementation• Early Implementation• Procurement• Secondary ImplementationAdoption• Voluntary Diffusion• Advisory Diffusion• Mandatory DiffusionDiffusionFocusofSSCIFSSCIF Focus within the stages of Innovation
    • 8. SSCIF will test innovations at these stages:• Proof of ConceptEffectivenessEvaluation• Proof of ImpactEffectivenessTesting• Post launch evaluationInnovationImplementation• Early adopterimplementationEarlyImplementationAdoption
    • 9. SSCIF - Benefits• Creation of an evidence base for use in national commissioning decisionswhich will result in rapid, widespread adoption of proven innovations in theNHS.• Earlier access to innovative care for patients.• Increased value for money to the NHS.• Increase knowledge of offer and impact of individual innovations/products9
    • 10. ProcessdecisionSimple on-line Step 1: Self-AssessmentStep 3: Detailed Submission (Table top expert reviewStep 2: Qualifying Submission Form (CRG Chair reviews)
    • 11. Process• Open to healthcare staff, manufacturers, clinicians, researchers, patientgroups and commissioners.• Submissions can be made anyone at Steps 1 and 2, but by Step 3, apractising Lead Healthcare Practitioner employed by a healthcareorganisation that supports the generation of wealth in the UK will need tosponsor and agree to lead the project.• Manufacturers and others can form alliances with health staff to do this.Medical Directors of the Healthcare Lead’s organisation will need to endorsethe submission.
    • 12. Funded Projects - documents and requirementsdecisionFunded SSCIF Evaluation Projects will have a Service Level Agreementwith a contract schedule taken from the Step 3: Detailed SubmissionForm detailing the key activities, key milestones, intended outcomes andkey performance indicators.Lead Applicants will be provided with sample templates for: A project initiation document A protocol for local ethical approval Informed Consent and patient participation Data set for Patient Information Leaflets Headings for final report including final products, factors for successetc.
    • 13. SSCIF Next Steps
    • 14. Innovation Health and Wealth• UK Plan for Growth March 2011– Challenged NHS CE to review adoption and diffusion ofinnovation• Prompted the NHS CE Review– Asked major stakeholders what might be done toaccelerate the spread of innovations in the NHS– Consultation across NHS, Government, Industry,Academia and Patient Groups– 310 responses received; 28% from industry (Incl Med Tech)– 17% of respondents identified the need for innovationfunds (including a specific fund for Specialised Services)• Resulted in IHW (Dec 2011)– 31 Actions to drive the adoption and diffusion of innovation
    • 15. Reason for the SSCIF• Many innovations with promise available to the NHS– But often languishing at a local/regional level– No widespread uptake due to lack of commissioningevidence• Evidence Generation in Specialised Services oftendifficult– Low volume– Hard to achieve levels of evidence similar to thosegenerated by RCTs– Even data (incl. RCTs) sufficient for MA are often notenough to convince commissioners of the innovation’svalue in clinical practice
    • 16. Ethos of the SSCIF• Aid accelerated adoption and diffusion of transformationalinnovations– Generate evidence on the value of promising innovationsthat are available for use in the NHS– To enable evidence based commissioning decisions to be made– Make use of New Structure– National commissioning decisions for specialised services– Set a paradigm for adoption and diffusion of innovation in aclinically led fashion
    • 17. Another Hurdle?• No!!• In the past– Drugs not considered by NICE or not recommended due tolack of evidence– Commissioning considered independently by 10 SCGs– Each following a different process (rarely evidence generating)– Potential for 10 different decisions• Now– 1 National decision on specialised services commissioning– Must be based on robust evidence– How can this be obtained if not a NICE topic or not recommendeddue to lack of evidence• The SSCIF is a real opportunity
    • 18. Silo Busting• SSCIF Evaluation Projects will:– Look at complete patient pathway, taking into account:– Impact of the innovation on outcomes; and– Cost and efficiency; and– Activity levelsacross all parts of the pathway– Consider:– Societal Impacts– Gaps in service provision (degree of unmet need)– Generate evidence to fill data gaps that are preventingcommissioning– Data gaps on effectiveness and costs in the NHS
    • 19. Real Opportunity for Partnership• The SSCIF aims to generate evidence that is:– Is needed by NHS England for national commissioning decisionsin the new structure– Could benefit the manufacturer once generated• Therefore generation of evidence should be funded jointly– NHS England has set up a fund (SSCIF) to generate theinformation it needs for all innovations– Manufacturers should not rely wholly on NHS funding to generatedata on their products (State Aid)– So for commercial applications to the SSCIF, the evaluationprojects will need to be jointly funded by the applicant and by theSSCIF
    • 20. Unrivalled potential• A successful evaluation project will result in– National Commissioning Policy– potentially a National commissioning decision.– This is unlike anything seen before in specialised services• The partnership ethos will extend to commissioningarrangements post SSCIF evaluation– Exclusivity terms– Discounted purchase price

    ×